Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy

MeSH terms

• Administration, Oral
• Anticoagulants / therapeutic use*
• Benzimidazoles / administration & dosage
• Benzimidazoles / adverse effects
• Dabigatran
• Elective Surgical Procedures
• Factor Xa Inhibitors
• Fibrinolytic Agents / administration & dosage*
• Fibrinolytic Agents / adverse effects*
• Hemorrhage / chemically induced
• Hemorrhage / etiology*
• Heparin, Low-Molecular-Weight / administration & dosage
• Heparin, Low-Molecular-Weight / adverse effects
• Humans
• Ischemic Attack, Transient / prevention & control
• Medical Records / standards*
• Morpholines / administration & dosage
• Morpholines / adverse effects
• Perioperative Period*
• Pyrazoles / administration & dosage
• Pyrazoles / adverse effects
• Pyridines / administration & dosage
• Pyridines / adverse effects
• Pyridones / administration & dosage
• Pyridones / adverse effects
• Risk Assessment
• Rivaroxaban
• Stroke / prevention & control
• Thiazoles / administration & dosage
• Thiazoles / adverse effects
• Thiophenes / administration & dosage
• Thiophenes / adverse effects
• Thromboembolism / etiology
• Thromboembolism / prevention & control*
• beta-Alanine / administration & dosage
• beta-Alanine / adverse effects
• beta-Alanine / analogs & derivatives